Monopar Therapeutics’ (NASDAQ:MNPR) quiet period will expire on Tuesday, January 28th. Monopar Therapeutics had issued 1,111,112 shares in its initial public offering on December 19th. The total size of the offering was $8,888,896 based on an initial share price of $8.00. During Monopar Therapeutics’ quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Shares of NASDAQ:MNPR opened at $16.50 on Monday. Monopar Therapeutics has a 1 year low of $8.35 and a 1 year high of $48.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that has completed Phase II for the treatment of chemoradiation-induced severe oral mucositis; Camsirubicin, a proprietary doxorubicin analog that is in Phase II clinical trial for the treatment of adult and pediatric solid, and blood cancers; and MNPR-101, a humanized monoclonal antibody for treating cancer.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.